[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vision-loss-partial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vision-loss-partial":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,76,148,191,221],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":37,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100619218","brain-stimulation-effects-on-orientation-and-mobility-skills-in-adults-with-vision-impairment-100619218",false,"NCT07341763","Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment","A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate Non-invasive Brain Stimulation Effects on Orientation and Mobility Performance in Adults With Visual Impairments","Inclusion Criteria:\n\n* Are healthy, capacitated adults with binocular constricted visual field loss (due to either retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma) resulting in functional vision losses. These individuals with visual impairments can be those who have been previously trained by an Orientation and Mobility (O\\&M) specialist to independently travel with the long white cane daily (since the length of the white cane and tip at the base are based on personal preference, they should be willing to use their own white cane for the study), and those who do not necessarily use a cane for travelling.\n* Have binocular visual acuity or best corrected binocular visual acuity no worse than 6\u002F12 or 20\u002F40 or +0.30 logMAR (inclusive) with no eccentric viewing and binocular visual fields no better than 50 degrees in total in each eye as given by the Humphrey Field analyzer and no better than 50 degrees binocularly as given by arc perimeter test. The Humphrey Field Analyzer measures static visual field test, whereas the Arc perimeter test measures kinetic visual field test. Measuring kinetic and static visual field would promote a greater understanding of the individual's daily performance.\n* Are over the age of 18 (inclusive) and has full legal capacity to provide informed consent.\n* Have read and fully comprehends the information in the consent letter.\n* Are willing and capable of adhering to instructions and maintaining the outlined appointment schedule.\n\nExclusion Criteria:\n\n* Are involved in other recent eye-related studies, either clinical or research-related. To be eligible they would have to wait at least one week for studies not involving brain stimulation, and four weeks for studies in which they receive brain stimulation before they could participate in this study.\n* Have been diagnosed with dementia or self-reported dementia with no formal diagnosis.\n* Have been diagnosed with a cognitive impairment or self-reported cognitive impairment with no formal diagnosis.\n* Have been diagnosed with physical or motor impairments resulting in walking and\u002For balancing issues or self-reported physical or motor impairments resulting in walking and\u002For balancing issues with no formal diagnosis.\n* Have been diagnosed with vestibular disorders or dysfunctions which affects one's balance and\u002For mobility or self-reported vestibular disorders or dysfunctions which affects one's balance and\u002For mobility with no formal diagnosis.\n* Are unable to follow the researcher's instructions.\n* Are anticipating treatment (including ocular surgery) for any eye disease within the duration of the study.\n* Have any ocular pathology in addition to retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma, which can diminish their visual acuity and\u002For their visual field, however wearing glasses or contact lenses, as well as mild cataract of grade 2 or below is acceptable.\n* Have severe hearing impairment.\n* Are pregnant or trying to get pregnant.\n* Fit any of the typical contraindicators for brain stimulation. See contraindicator section below.\n\nFor all participants the contraindications for brain stimulation are:\n\n* Diagnosed with epilepsy or have previously experienced an epileptic seizure.\n* Implanted medication pump or implanted electronic device, including defibrillator or pacemaker.\n* Any metal implants in the head (excluding tooth fillings).\n* Active electric implants anywhere in the body (especially the head region).\n* On psychoactive medication for any psychiatric or neurological conditions including but not limited to depression and schizophrenia.\n* Areas of sensitive skin located on the face or head, or a skin condition on the face, or regularly use medication to alleviate skin irritation on the face.\n* Recurring headaches.\n* Previous head injury or skull fracture or head\u002Fbrain surgery.\n* Heart disease, neurological condition, or a history of cardiac or neurological surgery.\n* Current or historical cancerous or noncancerous brain tumor, or other abnormalities in brain structure.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O\\&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the participants receive active stimulation, and one in which the participants receive placebo (sham) stimulation. Stimulation will be administered in a randomized, double-blind order. To evaluate improvement, various measures of O\\&M performance will be assessed on a standardized obstacle course featuring static natural and artificial obstacles at defined intervals after the intervention. We hypothesize that the application of hf-tRNS to V1 will improve the orientation and mobility skills of individuals with constricted visual fields immediately following stimulation as a results of enhanced periphery through modulation of the mechanisms responsible for crowding, thereby reducing crowding effects and improving contrast for individuals with rod-cone dystrophy and RP (genetic conditions), whereas for individuals with glaucoma (a neurogenerative condition), any improvement noted would be attributed to be enhanced processing of visual signal in the affected periphery. The results will inform the design of a future, larger-scale study.",[26,27,28,29,30,31,32,33,34,35,36],"Retinitis Pigmentosa (RP)","Rod Cone Dystrophy","Visually Impaired Persons","Peripheral Visual Field Defect of Both Eyes","Low Vision, Both Eyes","Vision Loss Partial","Orientation","Mobility Difficulty","Mobility Limitation","Mobility and Independence","Glaucoma",[26,38,39,28,29,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63],"Rod Cone dystrophy","Advanced Glaucoma","Low Vision, Both eyes","Brain stimulation","tES","tRNS","hf-tRNS","transcranial electrical stimulation","transcranial random noise stimulation","high-frequency transcranial random noise stimulation","Long white cane","white cane","mobility cane","walking","orientation and mobility","orientation","mobility","low vision","vision loss partial","occipital pole","primary visual cortex","V1","neuroplasticity","mobility difficulty","mobility limitation","mobility and independence","RECRUITING","2026-06-30",{"date":67,"type":68},"2026-07-01","ACTUAL",{"date":67,"type":20},{"date":71,"type":20},"2027-08-31",{"name":73,"class":74},"University of Waterloo","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":105,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":147},"100286660","stem-cell-ophthalmology-treatment-study-ii-100286660","NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.",{"count":85,"type":20},500,[23],"This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[89,90,91,92,93,94,95,96,36,97,98,99,31,100,101,102,103,104],"Retinal Disease","Age-Related Macular Degeneration","Retinitis Pigmentosa","Stargardt Disease","Optic Neuropathy","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Leber Hereditary Optic Neuropathy","Blindness","Vision Loss Night","Vision, Low","Retinopathy","Maculopathy","Macular Degeneration","Retina Atrophy",[106,107,108,109,110,111,112,113,114,89,103,115,116,117,118,119,120,121,122,123,91,92,124,125,126,102,96,95,93,127,128,129,130,131,132,133,134,135,97,98,136,104],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Geographic Atrophy","Dry Macular Degeneration","Wet Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss","2026-06-24",{"date":139,"type":68},"2026-06-29",{"date":141,"type":68},"2016-01",{"date":143,"type":20},"2028-07-31",{"name":145,"class":146},"MD Stem Cells","INDUSTRY",4,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":155,"sex":16,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":173,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":75},"100519758","vision-loss-impact-on-navigation-in-virtual-reality-100519758","NCT06047717","Vision Loss Impact on Navigation in Virtual Reality","The Impact of Vision Loss on Naturalistic Behavior and Navigation in Virtual Reality","Cortically Blind Group:\n\nInclusion Criteria:\n\n* Residents of the United States or Canada\n* Presence of one-sided stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range of 21 - 75 years (verified by MRI and\u002For CT scans)\n* Reliable visual field defects in both eyes (homonymous defects) as measured by Humphrey or equivalent perimetry.\n* Willing, able, and competent to provide their own informed consent\n* Cognitively able, responsible to understand written and oral instructions in English\n* Emmetropic or else wear corrective contact lenses inside the virtual reality headset\n\nExclusion Criteria:\n\n* Those who have never driven or earned a drivers' license\n* Past or present ocular disease interfering with visual acuity\n* Best corrected visual acuity (BCVA) worse than 20\u002F40 in either eye\n* Sustained damage to the dorsal lateral geniculate nucleus\n* Presence of diffuse, whole-brain degenerative processes\n* Presence of brain damage deemed by study staff to potentially interfere with outcome measures\n* History of traumatic brain injury\n* Documented history of drug\u002Falcohol abuse\n* Diagnosis of cognitive or seizure disorders\n* Diagnosis of one-sided attentional neglect\n\nControl Group:\n\nInclusion Criteria:\n\n* Normal or corrected-to-normal vision, who are between the ages of 21 and 75 years of age, roughly matched to the age of CB subjects enrolled above\n* Competent and responsible, as determined by the Principal Investigator\n* Willing, able, and competent to provide their own informed consent\n* Normal cognitive abilities, be able to understand written and oral instructions in English\n* Emmetropic or else wear corrective contact lenses inside the virtual reality headset\n\nExclusion Criteria:\n\n* Subjects who have never driven or earned a drivers' license\n* BCVA worse than 20\u002F40 in either eye\n* Presence of vision loss from ocular diseases or disorders\n* Presence of a visual field defect\n* Inability to wear corrective contact lenses inside the virtual reality helmet if required to see clearly\n* Subjects with a history of neurological disorders\n* Subjects with a history of TBI\n* Persons who lack the competence or are otherwise unable to perform the visual testing as directed.",true,"21 Years","75 Years",{"count":159,"type":20},40,[23],"The purpose of this research is to better understand the impact of cortically-induced blindness (CB) and the compensatory strategies subjects with this condition may develop on naturalistic behaviors, specifically, driving. Using a novel Virtual Reality (VR) program, the researchers will gather data on steering behavior in a variety of simulated naturalistic environments. Through the combined use of computer vision, deep learning, and gaze-contingent manipulations of the visual field, this work will test the central hypothesis that changes to visually guided steering behaviors in CB are a consequence of changes to the visual sampling and processing of task-related motion information (i.e., optic flow).",[163,164,165,166,167,168,169,170,31,171,172],"Stroke, Ischemic","Quadrantanopia","Hemianopsia, Homonymous","Hemianopia, Homonymous","Hemianopia","Hemianopsia","Occipital Lobe Infarct","Visual Field Defect, Peripheral","Quadrantanopsia","Stroke Hemorrhagic",[174,175,176,177,178,179,180,181],"Occipital stroke","Vision loss after stroke","Vision recovery","Vision restoration","Partial vision loss","Homonymous quadrantanopsia","Homonymous quadrantanopia","stroke","2026-01-07",{"date":184,"type":68},"2026-01-09",{"date":186,"type":68},"2023-11-28",{"date":188,"type":20},"2028-10",{"name":190,"class":74},"University of Rochester",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":155,"sex":16,"minAge":156,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":203,"conditions":204,"keywords":209,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":75},"100603304","mechanisms-of-visual-restoration-after-occipital-stroke-100603304","NCT07134777","Mechanisms of Visual Restoration After Occipital Stroke","Mechanisms of Visual Restoration After Occipital Stroke (MOVROS)","MOVROS","Cortically Blind Subjects (n=50)\n\nInclusion:\n\n* Subjects between 21 and 80 years of age\n* Subjects must be residents of the United States or Canada\n* Subjects must exhibit unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range of 21 - 80 years (verified by MRI and\u002For CT scans)\n* Subjects with reliable visual field defects in both eyes (homonymous defects) as measured by Humphrey, MAIA, Goldmann, and\u002For equivalent perimetry. This deficit must be large enough to enclose a 5-deg diameter visual stimulus.\n* Subjects must be able to fixate on visual targets reliably for 1000ms, with jitter over less than 1-deg of visual angle.\n\n  o Note: This will be initially assessed by review of visual field reports as supplied by subjects during the screening process. However, we will be unable to fully assess their fixation ability until they start the psychophysics testing in our lab. If at that time we discover that they are unable to maintain adequate fixation, they will be withdrawn from the study.\n* Subjects must be willing, able, and competent to provide their own informed consent\n* Subjects must have their own home computer (desktop or laptop) and reliable internet access\n* All subjects must have normal cognitive abilities and memory, sufficient to be able to understand and follow written and oral instructions in English, as well as to remember how to complete visual training at home, on their own, as instructed, for several months.\n* Justification: We can only accept English-speaking subjects due to a lack of resources for supporting those who would require interpreter services. As all of our subjects are required to spend 3-5 days in lab with rigorous testing and training requirements, we must be able to communicate clearly and with minimal misunderstandings. This would require for up to 5-full days of in person interpreter services, for which we do not have funding. Additionally, ongoing communications take place by phone, email, and\u002For text as a part of home training (for routine check-ins and technical support for example) in the intervals between laboratory visits. This would require us to essentially have \"on demand\" access to interpreter services, which is simply not feasible.\n* Subjects must be safe and willing to undergo magnetic resonance imaging (MRI) scans\n\nExclusion:\n\n* Subjects who have past or present ocular disease interfering with visual acuity\n* Subjects with best-corrected visual acuity (BCVA) worse than 20\u002F40 in either eye\n* Subjects who have documented or suspected damage to the dorsal Lateral Geniculate Nucleus\n* Subjects who have diffuse whole-brain degenerative processes\n* Subjects who have experienced traumatic brain injury\n* Subjects who have any other brain damage deemed by study staff to potentially interfere with training ability or outcome measures\n* Subjects who have oculomotor defects deemed by study staff to potentially interfere with training ability or outcome measures (i.e., by impairing stable fixation during testing or training)\n* Subjects who have documented history of drug\u002Falcohol abuse\n* Subjects who are currently taking neuroactive medications which would impact training, as determined by PI\n* Subjects who have cognitive, memory or seizure disorders\n* Subjects with one-sided attentional neglect\n* Subjects who lack the competence or are otherwise unable to perform the visual training exercises as directed.\n* Subjects who have contradictions to MRI scanning will be excluded. These contraindications include: a) central nervous system aneurysm clips; b) implanted neural stimulator; c) implanted cardiac pacemaker or defibrillator; d) cochlear implant; e) ocular foreign body (e.g., metal shavings); f) insulin pump; g) metal shrapnel or bullet; h) any implanted device that is incompatible with MRI.\n* Subjects who have conditions that preclude MRI scanning, e.g., morbid obesity, claustrophobia.","80 Years",{"count":201,"type":20},100,"OBSERVATIONAL","This project will collect brain imaging data to quantify the effects of early visual cortex damage and visual training interventions on the structure and function of the residual visual system. Our goal is to improve understanding of the consequences of permanent visual cortex damage in humans, and to understand how visual training impacts the function of the residual visual system to restore perception.",[205,206,31,207,167,208,169],"Cortical Blindness","Stroke Ischemic","Visual Fields Hemianopsia","Hemianopia Homonymous",[210,211,212],"occipital stroke","vision loss","Homonymous quadranopsia","2025-11-26",{"date":215,"type":68},"2025-12-04",{"date":217,"type":68},"2025-10-17",{"date":219,"type":20},"2029-08-01",{"name":190,"class":74},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":155,"sex":16,"minAge":156,"maxAge":199,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":75},"100525398","effect-of-visual-retraining-after-stroke-100525398","NCT06121219","Effect of Visual Retraining After Stroke","Effect of Visual Retraining on Visual Loss Following Cortical Damage","urochester","Cortically Blind Subjects\n\nInclusion:\n\n* Between 21 and 80 years of age\n* Residents of the United States or Canada\n* Unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range (21-75 years)\n* Reliable visual field defects in both eyes as measured by Humphrey, MAIA, Goldmann, and\u002For equivalent perimetry, large enough to enclose a 5-deg diameter visual stimulus.\n* Able to fixate on visual targets reliably for 1000ms\n* Must have a home computer (desktop or laptop) and reliable internet access\n* Willing, able, and competent to provide informed consent\n* Normal cognitive abilities, able to understand written and oral instructions in English, and competent and responsible adults in order to complete the visual training at home, independently, as instructed, for several months.\n\nExclusion:\n\n* Past or present eye disease interfering with visual acuity\n* BCVA worse than 20\u002F40 in either eye\n* Damage to the dorsal Lateral Geniculate Nucleus\n* Diffuse whole brain degenerative processes\n* History of traumatic brain injury\n* Any other brain damage deemed by study staff to potentially interfere with training ability or outcome measures\n* Documented history of drug\u002Falcohol abuse\n* Currently taking neuroactive medications which would impact training, as determined by PI\n* Presence of cognitive or seizure disorders\n* One-sided attentional neglect\n* Subjects who lack the competence or are otherwise unable to perform the visual training exercises as directed.\n\nControl Subjects (n = 50)\n\nInclusion:\n\n* Between 21 and 80 years of age\n* Report no history of neurological disorder.\n* Competent and responsible, as determined by the Principal Investigator.\n\nExclusion:\n\n* Presence of damage to the visual system\n* Presence of an active disease process involving their nervous system.\n* Cognitive or seizure disorders\n* Best corrected visual acuity worse than 20\u002F40 in either eye\n* Presence of vision field loss from ocular disease or disorder",{"count":201,"type":20},[23],"This project is intended to collect data using standard clinical tests and psychophysics to quantify the effect of visual cortical damage on the structure of the residual visual system, visual perception, spatial awareness, and brain function. The investigators will also assess the effect of intensive visual retraining on the residual visual system, processing of visual information and the use of such information in real-world situations following damage. This research is intended to improve our understanding of the consequences of permanent visual system damage in humans, of methods that can be used to reverse visual loss, and of brain mechanisms by which visual recovery is achieved.",[31,233,208,167,164,163,234,205],"Vision; Loss, Both Eyes","Stroke - Occipital Infarction","2025-07-10",{"date":237,"type":68},"2025-07-16",{"date":239,"type":68},"2024-09-05",{"date":241,"type":20},"2032-01",{"name":190,"class":74}]